• LAST PRICE
    0.4401
  • TODAY'S CHANGE (%)
    Trending Up0.0001 (0.0227%)
  • Bid / Lots
    0.4400/ 21
  • Ask / Lots
    0.4430/ 2
  • Open / Previous Close
    0.4400 / 0.4400
  • Day Range
    Low 0.4398
    High 0.4460
  • 52 Week Range
    Low 0.2303
    High 1.2000
  • Volume
    57,658
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.44
TimeVolumeSIOX
09:32 ET14890.44
09:33 ET24160.4431
09:48 ET499130.4398
09:50 ET1000.44
10:04 ET1000.4448
10:08 ET12000.44
10:11 ET2000.4401
10:18 ET1000.4447
10:22 ET3590.4446
10:38 ET10000.4401
10:51 ET3000.4401
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSIOX
Sio Gene Therapies Inc
32.5M
-0.6x
---
United StatesCOEP
Coeptis Therapeutics Holdings Inc
32.3M
15.6x
---
United StatesEQ
Equillium Inc
34.3M
-0.4x
---
United StatesCVKD
Cadrenal Therapeutics Inc
29.9M
0.0x
---
United StatesMBRX
Moleculin Biotech Inc
36.1M
-1.4x
---
United StatesSHPH
Shuttle Pharmaceuticals Inc
28.1M
0.0x
---
As of 2023-01-31

Company Information

Sio Gene Therapies Inc. is a clinical-stage company. The Company is focused on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. The Company is primarily focused on pre-clinical research and development initiatives in gene therapy.

Contact Information

Headquarters
1501 Broadway, 12Th FloorNEW YORK, NY, United States 10036
Phone
302-636-5400
Fax
302-636-5454

Executives

Chairman of the Board
Frank Torti
Chief Executive Officer, Director
Pavan Cheruvu
Chief Financial Officer, Chief Accounting Officer, General Counsel
David Nassif
Chief Research and Development Officer
Gavin Corcoran
Lead Independent Director
Atul Pande

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$32.5M
Revenue (TTM)
$0.00
Shares Outstanding
74.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.54
EPS
$-0.68
Book Value
$0.82
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.